RECEIL

NOV 0 6 200U

	_						_		TECH CENTER	609/2900 of 18
						ATTY. DOCKET NO. 0609.4830001			ATION NO.	01A
				PTO-1449	· WENT	APPLICANT Aghi et al.	<del></del>		E N	ov , S
	11	NFURMAII	UN DIS	CLOSURE STATE	<u>:MENI</u>	FILING DATE July 14, 2000		GROUP 1634	1632	7700 8
					U.S.	PATENT DOCUMENTS				CEE TO SEE
EXAMINE		Τ	T <sub>non</sub>	MENT NUMBER	DATE	NAME	CLA	.ee	SUB-CLASS	MARK CATE
INITIAL		AA1	1	MENT NUMBER 9,774	DATE 06/25/1996	Barba et al.	424		93.21	08/13/1991
Qu	<u> </u>	AB1		1,624	01/07/1997	Barber et al.	435		240.2	11/23/1993
		AC1		1,818	02/11/1997	Freeman et al.	424		93.21	12/08/1994
	<del></del>	AD1	+-	1,236	05/20/1997	Woo et al.	514		44	08/26/1993
	<del>                                     </del>	AE1	+-	0,488	09/23/1997	Gregory et al.	514	,	44	10/13/1993
<del></del>		AF1	+ -	8,773	11/18/1997	Chiocca et al.	514	,	44	10/28/1994
	<u> </u>	AG1	+	1,177	11/25/1997	Guber et al.	435	i	172.3	06/05/1995
	1	AH1	1	1,486	04/21/1998	Pathak et al.	424	,	93.21	06/06/1995
,	<b>√</b>	AI1	5,76	3,217	06/09/1998	Cynader et al.	435		69.1	10/11/1995
Ø	201	AJ1	5,76	3,242	06/09/1998	Zhang et al.	435	1	172.3	02/08/1995
		AK1								
					FOREI	GN PATENT DOCUMENTS		<u></u>		
EXAMINE INITIAL			DOCU	MENT NUMBER	DATE	COUNTRY	CLA	ss	SUB-CLASS	TRANSLATION
Q	N	AL1	WO 9	5/06486	03/09/1995	WIPO				Yes No
		АМ								Yes No
		AN								Yes No
	-	AO			<u> </u>					Yes No
		АР						_		Yes No
				OTHER (	Including Author	, Title, Date, Pertinent Pages,	etc.)	ı		
QN	J	AR	1 .	Abdallah, B. therapy," B	. et al., "Non-vi iol. Cell 85:1-7	ral gene transfer: Application (1995).	s in d	evelopm	ental biolog	gy and gene
Qn	J	AS	1	Aghi, M. <i>et</i> Fluorocytosi	al., "Synergisti ine/Cytosine Deam	c Anticancer Effects of Gancic ninase Gene Therapies," <i>J. Natl</i>	lovir/1 . Cance	Thymidi er Inst.	ne Kinase ar . 90:370-380	nd 5- (March 1998).
Q	N	AT	1 :			lutamyl Synthetase Gene Transf 1. Cancer Inst. 91:1233-1241 (J			Antifolate	Sensitivity in
EXAMINE	ER .	Q.	100	, Neu	ver—	1.04		CONSIDE		
EXAMINE	R: Init	tial if	refere	te considere	ed, whether or no onsidered. Inclu	ot citation is in conformance wade copy of this form with next	ith MP	EP 609. nicatio	Draw line n to Applica	through

NOV 0 6 2000

		<u>.</u>	<del></del>	-	ATTY. DOCKET NO. 0609.4830001	-	<b>483H C</b> 09/617	INTER 1600/25	Page 2 of 18
		FORM F	РТО-1449		APPLICANT			1	
<u> 1</u>	NFORMAT	ON DIS	CLOSURE STATE	EMENT	Aghi <i>et al</i> .  FILING DATE .		GROUP	A Nov	0 2 2000 &
					July 14, 2000		1614		<i>y</i>
				U.S.	PATENT DOCUMENTS	· · · · · · ·		No.	EMARK CITY
EXAMINER		000	MENT NUMBER	DATE	NAME	CLA	99		FILING DATE
INITIAL	AA	DOCO	MENT NUMBER	DATE	NAPIC	100		OOD CEAGO	TILING DIVI
	AB	1					-		
	AC								
	AD								
	AE						-		
	AF								
	AG	<del></del>							
	AH	<del>                                     </del>		<del></del>		<del></del>			
	AI	_		<del>-</del>	<del> </del>				
	AJ AK			-					
	Į AK	<u> </u>		FORE I	GN PATENT DOCUMENTS				
EXAMINER	1				-			-	
INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLA	SS	SUB-CLASS	TRANSLATION
	AL								Yes No
·	1								Yes
	AM	-	<del></del>						No
	AN								Yes No
									Yes No
,, ,	AO	<del>                                     </del>							Yes
	AP	<u> </u>			Tink Date Date D				No
	T		OTHER (	Including Author	, Title, Date, Pertinent P	ages, etc.)	<u> </u>	<del> </del>	·
Qn	AR	<u>2</u>	Aghi, M. <i>et</i> (May-June 20	al., "Prodrug ac	tivation enzymes in cancer	r gene there	а <b>ру,</b> " <i>J</i> .	Gene Med.	2: 148-164
an	AS	2	Barredo, J. Synthetase (1992).	and Moran, R.G., Activity during C	"Determinants of Antifold Cellular Proliferation and	ate Cytotox Developmen	icity: F t," Mole	folylpolyglu ec. Pharmaco	itamate 1. 42:687-694
QN	AT	2 :	Calos, M.P. Trends in Ge	et al., "The pot enetics 12:463-46	ential of extrachromosomal 7 (1996).	l replicatin	ng vecto	ors for gene	therapy,"
EXAMINER (	کیده.		me				CONSIDE	RED よし	
EXAMINER: Ini	tial if	refere	nce gansider	ed, whether or no	ot citation is in conformar	nce with MPI	EP 609.	Draw line	through
citation if no	t in cor	nforman	ce and not co	onsidered. Inclu	de copy of this form with	next commu	ncation	i to applica	HIL.

NOV 0 6 2000

Page 3 of 18

			70.1//0		ATTY. DOCKE 0609.483000		APPLI (TEC2H	CATION NO 072	100 A
			TO-1449	weut	APPLICANT Aghi <i>et al</i> .			₽ Nov	, S
<u> 11</u>	FORMATIC	N DIS	CLOSURE STATE	MENI	FILING DATE July 14, 20		GROUP 1614	The second second	7 200g W
				U.S.	PATENT DOCUME			T TO THE REAL PROPERTY.	CHI TO
EXAMINER			-				1		MARIN
INITIAL		DOCUI	MENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA AB								
	AC	<del> </del>				<del></del>			
	AD								
	AE								
	AF						_		
	AG	<u> </u>				· · · · · · · · · · · · · · · · · · ·			
	АН	<u> </u>	<del></del>				<u> </u>		
	AI_	ļ		· . <del>-</del>		<del> </del>	<del></del>		
	AJ						<u> </u>	<del> </del>	
	AK			FOREIG	N PATENT DOCU	MENTS	.1	<b>.</b>	
EXAMINER	T -	_		PORET	IN PAIENT DOCU	MEN I 3	1	1	
INITIAL		DOCUI	MENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	AM				-	· · ·			Yes No
					<u></u>				Yes No
	AN				<del></del>	= ,-			Yes
	AO		**				1		No Yes
	AP								No
			OTHER (	Including Author,	, Title, Date,	Pertinent Pages,	etc.)	.=	
an	AR	<u>3</u>	Chabner, B.A	A. et al., "Polyg	lutamation of	Methotrexate, $oldsymbol{U}$ $J$ .	Clin. Inve	st. 76:907-91	2 (1985)
	AS	<u>3</u>				int that delivers thechnol. 16:444-44		transgene and	d augments
on on	AT	<u>3</u>	Oxazaphospho	rines following	Cytochrome P-4	Activation and Enhances 650 Gene Transfer: " Cancer Res. 55:5	Developmen	t of a Combir	Effect of med
EXAMINER	(d)	e	Ne.				DATE CONSTI	DERED DU 97	
EXAMINER: Init	ial if i	efere	nce considere	ed, whether or no onsidered. Inclu	t citation is de copy of thi	in conformance wi	th MPEP 609 communicati	. Draw line on to Applica	through ant.

NON O & SOOR

							T		grade 4 01 10
					ATTY. DOCKET NO. 0609.4830001	_	A <b>PECH</b> 09/617	65167 NO.	OIPE
		FORM I	PTO-1449		APPLICANT				
<u> 11</u>	IFORMATIC	ON DIS	CLOSURE STATE	EMENT	Aghi et al.		- COOLID	<del>- 12 14</del>	OV 0 2 2000 8
					FILING DATE July 14, 2000		GROUP 1614	TEK "	2 2000
				U.S.	PATENT DOCUMENTS			· · · · · · · · · · · · · · · · · · ·	13
EXAMINER									QEMARK!
INITIAL	<b>├</b>	DOCU	MENT NUMBER	DATE	NAME	CL	ASS	SUB-CLASS	FILING DATE
<del>.</del> .	AA	╁—							
	AB	-							
	AC								
	AD	<b>-</b>		<del></del>				<del>                                     </del>	
	AE	+	<u></u>		<u> </u>			<u> </u>	
	AF	<b></b>	-	<del></del>			···	<del>                                     </del>	<del></del>
	AG							<del> </del>	
	AH	-	<u> </u>					<del> </del>	
	AI	<u> </u>						<del>                                     </del>	<del></del>
	AJ	-					-		
	AK							<u> </u>	L
	Т	1 -		FOREIG	GN PATENT DOCUMENTS			1	Γ
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION
-									Yes
	AL	_			· .	-			No Yes
	AM				:				No
	AN								Yes No
	AO								Yes No
	AP		-						Yes No
	I AP	<u> </u>	OTHER (	Including Author	, Title, Date, Pertinent F	Pages etc.	)		
		_	OTHER (	Thetaamy Rathor,	, Title, bate, Fertiment F	ages, etc.	<u>,                                     </u>		
aw	AR	<u>4</u>	Practice, 2º	Allegra, C.J., " d Edition, Chabne -148 (1996).	Antifolates," in Cancer Cier, B.A. and Longo, D.L.,	hemotherapy eds., Lippi	and Bio	otherapy: Pri aven Publish	inciples and ners, New York,
	AS	<u>4</u>	Dachs, G.U.	et al., "Targeti	ng Gene Therapy to Cancer	: A Review,	" Oncol	. Res. 9:313	-325 (1997).
V	AT	<u>4</u>	Danks, M.K. Cells to CP	et al., "Overexp T-11," Cancer Res	ression of a Rabbit Liver . 58:20-22 (January 1998).	Carboxyles	terase	Sensitizes H	luman Tumor
EXAMINER	6	), 42	. 2	~ -		DATE	CONSIDE	RED ON	
EXAMINER: Init	tial if	refere	ence consider	ed whether or no	ot citation is in conformande copy of this form with	nce with MF	PEP 609.	Draw line	through
CILACION IT NO	r in con.	ı orman	ico anti not co	onstucted. Inclu	ac copy or this form with	TONE COMMI		Applice	

Page 5 of 18

AL						ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 019					
FILLING DATE  U.S. PATENT DOCUMENTS    SUB-CLASS   PILLING DATE			FORM	PTO-1449		1			le un	` <u>4</u>	
U.S. PATENT DOCUMENTS  DOCUMENT NUMBER DATE MAME CLASS SUB-CLASS FILTING DATE  AA AB A	<u> 1</u>	NFORMAT I	ON DIS	CLOSURE STATI	<u>EMENT</u>			GROUP	H NOV	0 2 200n E	
DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE  AB AC								1614		<i>W</i>	
DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE  AB AC			-		U.S.	PATENT DOCUMENTS	<u> </u>			DANSK SEST	
AS AC			DOCL	JMENT NUMBER	DATE	NAME	CLA	ss	SUB-CLASS	FILING DATE	
AC  AD  AE  AF  AG  AG  AN  AN  AI  AI  AJ  AN  AK  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  AD  AN  AN  AN  AN  AN  AN  AN  AN  AN		AA									
AC AE AE AE AF AG AG AG AN		АВ								<u> </u>	
AR  AF  AG  AH  AI  AI  AI  AI  AI  AX  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  DOCUMENT NUMBER DATE  COUNTRY  CLASS  SUB-CLASS  TRANSLATION  Yes No  AN  AN  AN  TOTAL  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR  Deconarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244  (1995)." Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517  AT  Freeman, S.M. et al., "The Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  DATE CONSIDERED  DATE CONSIDERED  DATE CONSIDERED  FRANINER: Initial if Peterpne considered whether or not citation is in conformance with NPEP 609. Draw Line through		AC	ļ						<u> </u>		
AF AG AG AG AH AH AI	<u></u>	AD								<del>                                     </del>	
AA			-			<u> </u>			<del></del>	<del> </del>	
AN AI SAN FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL AL SUB-CLASS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION  TAM Yes No Yes No AN SUB-CLASS TRANSLATION  TAM SUB-CLASS SUB-CLASS TRANSLATION  TAM SUB-CLASS TRANSLATION  TOTAL YES NO YE			+				_				
AI AJ AJ BOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION  EXAMINER INITIAL  AL COUNTRY CLASS SUB-CLASS TRANSLATION  Yes No AM Pap THE Country Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517  AT 5 Freeman, S.M. et al., "The "Bystander Effect": Tumor Regression When a Fraction of the Tumor Mass  EXAMINER DATE COUNTRY  DATE CONSIDERED  DATE CONSIDERE		1	+	<del></del>			_				
AX  FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL  AL  AL  AN  AN  AN  AN  AN  AN  AN			╁				_ <del>-</del> -				
FOREIGN PATENT DOCUMENTS  EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION  Yes No AM Yes N		<del></del>	+			<del></del>					
EXAMINER  AL  AL  ADDITION  AN  AN  AN  AN  AN  AN  AN  AN  AN	<del></del>	1	+								
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION  AL Yes No  AM Yes No  AN Yes No  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deconarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The Bystander Effect": Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  DATE CONSIDERED.  EXAMINER Date of the Progress of the Progression of the State of the Progression When a Fraction of the Tumor Mass Date Considered whether or not citation is in conformance with MPEP 609. Draw Line through		1 44			FOREIG	ON PATENT DOCUMENTS	<del>"</del>	-	<u> </u>	<u> </u>	
INITIAL  DOCUMENT NUMBER DATE  COUNTRY  CLASS SUB-CLASS TRANSLATION  Yes No  AM  AM  AN  AN  AN  AN  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deconarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244  (1995).  AS  Deconarain, M.P. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517  AT  Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER. Initial if Exterence considered whether or not citation is in conformance with MEPE 609. Draw Line through	EXAMINER		T	***							
AN AN Yes No Yes No AN			DOCL	JMENT NUMBER	DATE	COUNTRY	CL/	ASS	SUB-CLASS		
AN Yes No  AN Yes No  AN Yes No  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deonarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).		Ai									
AN Yes No  AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deonarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  DATE CONSIDERED.  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through		-		4.00						Yes	
AND  OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deconarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  Freeman, S.M. et al., "The Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through		AM				······				Yes	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  AR 5 Deonarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER DATE CONSIDERED		AN	+-	<del>.</del>							
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)  Deonarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244 (1995).  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The Bystander Effect": Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through		AO	<u> </u>			<u> </u>			<u></u>	t	
Deonarain, M.P. et al., "Genetic Delivery of Enzymes for Cancer Therapy," Gene Therapy 2: 235-244  AS 5 Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw Line through		AP									
AS Drinkard, L. et al., "A Phase II Trial of Edatrexate (ETX) in Progressive Malignant Glioma (PMG)," Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  AT 5 Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through				OTHER (	Including Author	, Title, Date, Pertinent Pa	ges, etc.	)			
[PMG], " Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  [PMG], "Program/Proceedings of the American Soc. of Clinical Oncology 13:182, Abstract No. 517 (1994).  [Freeman, S.M. et al., "The 'Bystander Effect': Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified," Cancer Res. 53:5274-5283 (1993).  [EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through	SW)	AR	<u>5</u>		M.P. <i>et al</i> ., "Gen	etic Delivery of Enzymes fo	or Cancer	Therapy	" Gene Ther	rapy 2: <b>235-244</b>	
EXAMINER  DATE CONSIDERED  EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through		AS	<u>5</u>	(PMG)," Prog	. et al., "A Phas gram/Proceedings o	e II Trial of Edatrexate (E of the American Soc. of Clin	ETX) in Pr nical Oncol	ogressiv logy 13:	ve Malignant 182, Abstra	: Glioma ct No. 517	
EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through		AT	<u>5</u>	Freeman, S.I Is Genetica	M. <i>et al</i> ., "The ` lly Modified," <i>Ca</i>	Bystander Effect': Tumor Re ncer Res. 53:5274-5283 (199	egression 3).	⊌hen a l	Fraction of	the Tumor Mass	
EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through	EXAMINER D								REPOT		
	EXAMINER: Ini	tial if	refere	ence consider	ed whether or no	t citation is in conformand	ce with MP	EP 609.	Draw line n to Applica	through	

									Page 6 of 18
					ATTY. DOCKET NO. 0609.4830001		APPLIC 09/617	ATION NO.	OI.
			PTO-1449		APPLICANT Aghi et al.				Tr.
<u> 11</u>	IFORMAT I	ON DIS	CLOSURE STATE	EMENT	FILING DATE July 14, 2000		GROUP 1614	AND NOV	0 2 2000 8
	,							1	W
	T	ı		U.S.	. PATENT DOCUMENTS	·		TO STATE OF THE PERSON NAMED IN COLUMN TO STATE OF THE PE	MARKSIE
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CL	ASS	SUB-CLASS	FILING DATE
	AA	<b>†</b>							
	AB								
	AC								
	AD						<del></del>		
	AE								
	AF			<del></del>					
<u>-</u>	AG	┼	<del></del>						
	AH	+							
	AI			<del></del>					
	AJ	<b>├</b>					<del></del>	ļ. <u> </u>	<u> </u>
	AK			50951	CN DATENT DOCUMENTS	L		l	
	T	T		TOKE I	GN PATENT DOCUMENTS				
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN								Yes
	AO			· · · · · · · · · · · · · · · · · · ·					Yes
				· · · · · · · · · · · · · · · · · · ·					Yes
	AP	.1	OTHER (	Including Author	, Title, Date, Pertir	nent Pages, etc.	)		
<del></del>		l	OTHER (	The tading Addition	, Trete, bute, Teren	ione rages, oter			
CWO	AR	<u>6</u> '	Freeman, S.I (1996).	M. <i>et al</i> ., "In Si	itu Use of Suicide Ge	nes for Cancer 1	ſherapy,'	Semin. Onc	ology 23: <b>31-45</b>
	AS	<u>6</u>	Freemantle, Gene," J. B	S.J. and Moran, iol. Chem. 272:25	R.G., "Transcription 373-25379 (1997).	of the Human Fo	olylpoly	-γ-glutamate	e Synthetase
$\bigvee$	AT	<u>6</u>	Fry, D.W. <i>e</i> in Gut and 43:1087-109	the Ehrlich Tumo:	of the Role of Membra in Vivo as Factors	ane Transport amin Drug Sensitiv	nd Polyg vity and	lutamation o Selectivity	f Methotrexate

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

NOV 0 6 2000

						ATTY. DOCKET NO.  0609.4830001  APPLICATION NO.  09/617,116  O / A					
•			FORM F	rto-1449		APPLICANT				4./	
	INF	ORMATIC	N DIS	CLOSURE STATE	MENT	Aghi et al.	<del></del>		A NOV	5	
						FILING DATE July 14, 200	0	GROUF 1614	· E	2 2000 09	
					U.S.	PATENT DOCUMEN			E,	i S	
EXAMINER				<del></del>					ADEM	ABKIE	
INITIAL	_		DOCU	MENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE	
		AA	<u> </u>								
		AB	<u> </u>		<u> </u>						
		AC		<u></u>				<del> </del>	-	<u> </u>	
		AD							_ <del></del>	<del></del>	
		AE									
		AF	<u> </u>					<del>- </del>			
		AG					-		<del>- </del>		
	<del>  </del>	AH							-	<del></del>	
	$\overline{}$	AI	-					<del> </del>			
		AJ	_								
		AK			FOREIG	GN PATENT DOCUM	ENTE				
EXAMINER	1		Γ		FOREIG	GN PATENT DOCUM	ENIS		T		
INITIAL			DOCU	MENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION	
		AL								Yes No	
		АМ								Yes No	
		AN								Yes No	
		AO		· ·						Yes No	
				· · ·		_				Yes No	
		AP		ATUED (	I	Title Date I	Dontinent Deser	oto \	<u> </u>		
<del></del>				OTHER (	Including Author	, litle, Date,	Pertinent Pages,	etc.)			
OW	)	AR	<b>Z</b> ,	Garrow, T.A synthetase (1992).	. et al., "Expres and determination	sion cloning of n of its primary	f a human cDNA en y structure," <i>Prod</i>	coding foly c. Nat1. Ac	lpoly(y-gluta ad. Sci. USA	amate) 89:9151-9155	
	,	AS	<u>7</u> v		et al., "Regulati 1680-21685 (1993)		nd One-carbon Meta	abolism in	Mammalian Cel	lts," <i>J. Biol</i> .	
	/	AT	7	Lan, K-H. <i>e</i> for Human C	t al., "In Vivo S arcinoembryonic A	selective Gene E Antigen-producir	Expression and Th	erapy Media oma," <i>Cance</i>	ted by Adenov	viral Vectors 79-4284 (1997).	
EXAMINER		Qu		ممحكما					11240		
EXAMINER: citation if	Initi not	ial if i	refere	nce consider	ed, whether or no shsidered. Inclu	ot citation is independent	in conformance wi s form with next	th MPEP 609 communicati	. Draw line on to Applica	through ant.	

Page 8 of 18

					ATTY. DOCKET NO. 0609.4830001 APPLICATION NO 09/617,116					
			PTO-1449	·MENT	APPLIC Aghi e				RR NOV	ن کو در ا
1	IFURMA <u>I</u> II	<u> </u>	CLOSURE STATE	<u>:MENI</u>	FILING			GROUP 1614	夏	2 2000 W
				U.S.	PATENT [			1014	<b>V</b>	N SER
EXAMINER			······································						1	EMAST SIE
INITIAL	<b>├</b>	DOCU	MENT NUMBER	DATE	NAME		CLA	155	SUB-CLASS	FILING DATE
·	AA AB	1-								
	AC									
	AD									
	AE								<u> </u>	
	AF	ļ					_			
	AG	<b>_</b>								
	AH	<del> </del>								
-	AI	-							-	
	AJ AK	$\vdash$	<u> </u>	<u> </u>		*	<u></u>			
<u> </u>	I AK			FOREI	GN PATENT	DOCUMENTS	L	-		
EXAMINER								,		
INITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	COUNTRY	<del>_</del>	CLA	SS	SUB-CLASS	TRANSLATION
	AL									Yes No
			-							Yes No
	AM									Yes
	AN	<del>                                     </del>								No Yes
	AO	<del> </del>		-	-				<del> </del>	No Yes
·	АР									No.
			OTHER (	Including Author	, Title,	Date, Pertinent Pages	, etc.)			
On	AR	<u>8</u>	Li, WW. e Sarcomas," (	t al., "Mechanism Cancer Res. 52:14	ns of Natu 34-1438 (	ural Resistance to And 1992).	tifolat	es in H	uman Soft Ti	ssue
	AS	8	Matherly, L Dihydrofola 46:588-593	te Reductase as I	folate Po	olyglutamylation and ( Elements in Leucovor	Competi in Resc	tive Dro ue in L	ug Displacem 1210 Cells,'	nent at ' Cancer Res.
	AT	<u>8</u> '	McGuire, J. Sensitive a	J. and Russell, ( nd -Resistant Hum	C.A., "Fo nan Cell	lylpolyglutamate Synt Lines," <i>Oncology Res</i> .	hetase <i>10</i> :193	Express ·200 (19	ion in Antii 198).	folate-
EXAMINER		21.1	~e ~ A(	2 122		***	DATE	CONSIDE	RED 10	
EXAMINER: Initial if reference considered thether or no citation if not in conformance and not considered. Inclu						on is in conformance	with MP	EP 609.	Draw line	through
citation if no	t in con	Tormar	ice and not co	onsidered. Incl	ade copy	or this form with nex	COIIII		to Appere	<u> </u>

Page 9 of 18

			4//0		ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 09/617,116					
			PTO-1449		APPLICANT Aghi <i>et al</i> .					
<u> 1)</u>	IFORMAT I	ON DIS	CLOSURE STATE	<u>EMENT</u>	FILING DATE		GROUP	B NOV	0 2 2000	
	·				July 14, 2000		1614	- K		
EVANINED	<u> </u>	1		<u>u.s.</u>	PATENT DOCUMENTS	$\top$		T REAL	DA BY CHEY	
EXAMINER INITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	NAME	CL/	ss	SUB-CLASS	FILING DATE	
	AA	ļ						<u> </u>		
	AB	<u> </u>				-				
· · ·	AC	-			<u> </u>	-		<u> </u>		
	AD	╂				+		<u>.</u>	<del> </del>	
	AE AF	+	<del></del>			+				
	AG					十				
	AH			-		$\top$		*		
	AI		<del></del>							
	AJ									
	AK							<u></u>	<u> </u>	
				FOREIG	ON PATENT DOCUMENTS	- 1		r	т	
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CL/	ıss	SUB-CLASS	TRANSLATION	
	AL								Yes No	
<del></del>									Yes No	
	AM		····						Yes No	
	AN	$\vdash$				_			Yes	
	AO .	<del> </del>							No Yes	
	AP								No	
			OTHER (	Including Author	, Title, Date, Pertinent Pages,	etc.				
Sm)	AR	9	Miller, N. Genetic The	and Whelan, J., " rapy," <i>Hum. Gene</i>	Progress in Transcriptionally Ther. 8:803-815 (1997).	Target	ed and	Regulatable	Vectors for	
	AS	9	Moolten, F. Gene Ther.	L., "Drug sensiti 1:279-287 (1994).	vity ("suicide") genes for sel	ective	cancer	chemothera	py," Cancer	
	AT	9	Murdoch, B. packaging c	et al., "A rapid lones," <i>Gene Ther</i>	screening procedure for the id. 4:744-749 (1997).	dentif	ication	of high-ti	ter retrovirus	
EXAMINER	 (C	 ک	- NS	mal a		1 (	CONSIDE	الوليد		
EXAMINER: Init	tial if	refere	ence dongider	ed whether or no	ot citation is in conformance with copy of this form with next	ith MP	EP 609.	Draw line	through ant.	
CITACION II NO	. III CON	, or mai	DE GIRG HOL C							

Page 10 of 18

						<del></del>					
						ATTY. DOCKET NO. APPLICATION NO. 0609.4830001 09/617,116					
		FORM F	PTO-1449			PPLICANT		0,70	,,,,,	O LOCK	$\overline{}$
<u>11</u>	FORMAT I	ON DIS	CLOSURE STATE	MENT		ghi et al.			- R NOV		<del>&amp;}</del>
						ILING DATE uly 14, 2000		GROUP 1614	NOV	0 2 2000	99
				U.S.		TENT DOCUMENTS			E.		Ş
EXAMINER		DOCI	MENT NUMBER	DATE	NAM	ıF	CLAS	ss	SUB-CLASS	MARY SIE	ATE
INITIAL	AA	DOCO	MENI NUMBER	DATE	NAG	IL.	CLA	33	JOD CEASS	1121110	
	AB										
	AC								_		
	AD										
	AE							_			
	AF										
	AG									<u> </u>	
	AH				<u> </u>						
	AI				_		_	_		<del></del>	
	AJ	ļ							· · · · · ·		
	AK	:			<u> </u>						
57441155	1	T	-	FOREIG	GN P	ATENT DOCUMENTS			Γ	Γ	
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	cou	INTRY	CLAS	ss	SUB-CLASS	TRANSLAT	ION
	AL										Yes No
·											Yes No
	AM	+-		<u> </u>							Yes
	AN	┼									No Yes
	AO	$\vdash$				.440	<u> </u>			<u> </u>	No Yes
	AP										No
			OTHER (	Including Author	, Ti	tle, Date, Pertinent Pages, e	tc.)				
an	AR	<u>10</u> :	Nakanishi, I Systems 12:2	M. <i>et al.</i> , "Gene 263-310 (1995).	Intr	roduction Into Animal Tissues,	" Cr	it. Rev	. Therapeut	. Drug Car	rier
	AS	<u>10</u>		r., B.W. et al., 7-1741 (1996).	"Соп	mbination Gene Therapy for Ora	al Ca	ncer ir	n a Murine M	Model," Car	ncer
	AT	<u>10</u>	O'Malley, Ji Acad. Sci. 8	r., B.W. and Li, 342:163-170 (Apri	D., l 19	"Combination Gene Therapy for 998).	r Sal	ivary (	Gland Cance	r," Ann. N	'. <i>Y</i> .
EXAMINER D. D. D.						D	ATE	CONSIDE	1200/0	ת	
EXAMINER: Ini	tial if	refere	nce consider	ed, whether or no onsidered. Inclu	ot ci	itation is in conformance with copy of this form with next co	h MPE	P 6092	Draw line n to Applica	through	
1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	<u> com</u>										

Page 11 of 18

		<u> </u>			ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 09/617,116					
		FORM F	PTO-1449		APPLICANT				The state of the s	
<u>11</u>	NFORMATIO	ON DIS	CLOSURE STATE	MENT	Aghi <i>et al</i> .  FILING DATE		GROUP	B NOV	(1 2 S)	
	····				July 14, 2000		1614	NOV	0 2 200n G	
		,		U.S.	PATENT DOCUMENTS			<u> </u>	W .	
EXAMINER INITIAL	ļ	DOCU	MENT NUMBER	DATE	NAME	CLA	ss	SUB-CLASS	ARTHUR DATE	
	AA	ļ		-						
	AB	<u> </u>				-				
	AC	<del> </del>	<u> </u>			-				
	AD	<u> </u>				+			<u> </u>	
	AE	-	<u> </u>					<del>                                     </del>	<u> </u>	
	AF	╁				+		-		
	AG	+				_	-			
	AH AI	+	<u> </u>	<del>-</del>		+		-		
	AJ AJ					$\vdash$				
7.0	AK	1		<del>-</del>						
	I AK	<u>.</u>		FOREIG	GN PATENT DOCUMENTS	<u> </u>		<u> </u>		
EXAMINER		DOCI	MENT NUMBER	DATE	COUNTRY	CLA	ss	SUB-CLASS	TRANSLATION	
INITIAL		DOCO	MENT NUMBER	DATE	COOKINI	155		000 0000	Yes	
- 1	AL		<del>.</del>			<u> </u>		<u>.                                    </u>	No Yes	
-	АМ	-			-				No Yes	
	AN	ļ				<del> </del>			No	
	AO				·				Yes No	
	AP								Yes No	
	17		OTHER (	Including Author	, Title, Date, Pertinent Pages,	etc.				
CUD	AR	11	Peters, G.J	. and van der Wil	t, C.L., "Development of a Simple in Chemistry and biology of Pterpp. 651-654 (1993).	ole Fo	lvlpolv	glutamate Sy olates, Ayli	ynthetase Assay ng, J.E. <i>et</i>	
	AS	11	Pizzorno, G CCRF-CEM Ce (1988).	. <i>et al</i> ., "Impair lls after Short-T	ed Polyglutamylation of Methotr erm, High-Dose Treatment with 1	exate his D	as a Ca rug," Ca	ause of Resi ancer Res. 4	stance in 18:2149-2155	
	AT	11	Rainov, N.G Herpes Simp	. et al., "Retrov lex Virus-Thymidi	irus-Mediated Gene Therapy of E ne Kinase/Ganciclovir Paradigm,	xperi " Can	mental I cer Gene	Brain Neopla Therapy 3:	asms Using the 99-106 (1996).	
EXAMINER	B		~ iU	221		DATE	CONEIBE	TO SO	91	
EXAMINER: Ini	tial if	refere	nce consider	ed, whether or no	ot citation is in conformance winde copy of this form with next	th MP	EP 609.	Draw line	through	
citation if no	t in con	rormar	ce and not co	was ide ed. Hicko	de copy of this form with hext	- CHINA		to Appelo		

					ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 09/617,116				
		FORM F	PTO-1449		APPLICANT				Tr.
<u>11</u>	IFORMATI	ON DIS	CLOSURE STATE	MENT	Aghi <i>et al</i> .  FILING DATE		GROUP	E Nov	O 2 May Co
					July 14, 2000		1614	B	<u> </u>
EVANINED	Ι	Τ	. <u>.</u>	U.S.	PATENT DOCUMENTS			TO SO	le su CÉÉ
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	NAME	CL	ASS	SUB-CLASS	FILING DATE
	AA	-	·			<u>_</u>		<u> </u>	<del></del>
	AB	<del>                                     </del>							
	AC				·	·			
,	AD AE	<del>                                     </del>							
	AF								
	AG								
	АН	Ĺ							
	AI	<u> </u>							
•	AJ	ļ							
	AK	<u> </u>							
	<del>-</del>	T	<del></del>	FOREIG	ON PATENT DOCUMENTS			<del>-</del>	
EXAMINER INITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION
	AL								Yes No
									Yes No
	AM	<del>                                     </del>	·		-				Yes
·	AN						A		No Yes
	AO	├	-						No Yes
	АР								No
			OTHER (	Including Author	, Title, Date, Pertinent I	Pages, etc.	<u> </u>		
ew)	AR	<u>12</u>	Ram, Z. et o Rats," Cance	al., "In Situ Ret er Res. 53: <b>83-88</b>	roviral-mediated Gene Tra (1993).	nsfer for t	he Treat	ment of Bra	in Tumors in
	AS	<u>12</u> ,	Rancourt, C Approach fo	et al., "Endoth Carcinoma of th	elial Cell Vehicles for D e Ovary," <i>Clin. Cancer Re</i>	elivery of S. 4:265-27	Cytotoxi O (Febru	ic Genes as ary 1998).	a Gene Therapy
	AT	12	Robbins, P.I	o. et al., "Viral	vectors for gene therapy	, " TIBTECH	<i>16</i> :35-40	(January 1	998).
EXAMINER		C	21/2 226	10.11		DATE	CONSIDE	RED	lon
EXAMINER: Init	tial if	refere	nce consider	ed whether or no	t citation is in conforma de copy of this form with	ance with MF	EP 609.	Braw line	through
citation if no	in con	Torman	ice and not co	ovisioenea. Inclu	de copy of this form with	HEAL COURIL		. to Applica	

Page 13 of 18

						ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 09/617,116						
		FORM I	PTO-1449			APPLICANT Aghi et al.						
1)	IFORMAT I	ON DIS	CLOSURE STATE	<u>MENT</u>	F	FILING DATE GROU			E.	YOV 8 Z 2000 B		
<u> </u>			<del></del>									
EXAMINER	T	T		U.S.	PAI	TENT DOCUMENTS			<b>~</b>	QEMARK SE		
INITIAL		DOCU	MENT NUMBER	DATE	NAM	1E	CLA	ss	SUB-CLASS	FILING DATE		
	AA	<b>_</b>			_					<u> </u>		
	AB	+				-						
	AC	+				·						
	AD AE	-	<del></del>		-							
	AF				-					-		
	AG		<del></del>									
	АН _	1										
	AI											
	AJ	ļ										
	AK	<u> </u>										
	Т	<del>, -</del> -		FOREIC	GN P.	ATENT DOCUMENTS			<u> </u>	<del></del>		
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	cou	JNTRY	CLA	ss	SUB-CLASS	TRANSLATION		
	AL									Yes No		
	AM									Yes , No		
		1								Yes No		
	AN									Yes		
	AO		<del></del>							No Yes		
	AP									No		
			OTHER (	Including Author,	, Ti	tle, Date, Pertinent Pages, e	tc.)					
ou)	Rogulski, K.R. et al., "Glioma Cells Transduced with an Escherichia coli CD/HSV-1 TK Fusion Gene Exhibit Enhanced Metabolic Suicide and Radiosensitivity," Human Gene Ther. 8:73-85 (1997).									K Fusion Gene (1997).		
	AS	<u>13</u>	Roth, J.A. Lung Cancer	oth, J.A. et al., "Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with ung Cancer," Nature Med. 2:985-991 (1996).								
	AT	<u>13</u> ·	Roth, J.A. a Going?" J. /	Roth, J.A. and Cristiano, R.J., "Gene Therapy for Cancer: What Have We Done and Where are we Going?" J. Natl. Cancer Inst. 89:21-39 (1997).								
EXAMINER	0	110	10			D	ATE:	CORSIDE	124	(2)		
EXAMINER: Init	tial if	refere formar	ence considerence and not co	ed, whether or no onsidered. Inclu	ot ci	itation is in conformance with copy of this form with next co	n MPI	PO <sub>60</sub> .	Draw line n to Applica	through		
				<del></del>								

					<del> </del>				Page 14 of 18		
					ATTY. DOCKET NO. 0609.4830001		APPLICA 09/617,		0.7		
			PTO-1449		APPLICANT Aghi et al.  NOV 0 2 2000						
<u>1</u>	NFORMAT	ION DIS	CLOSURE STATE	<u>EMENT</u>	FILING DATE GROUP			The state of the s			
	<del></del>	<del></del>		II S	July 14, 2000  . PATENT DOCUMENTS		1614	- VA	QEMARK THEY		
EXAMINER	Τ	T		T	TATENT DOCUMENTO						
INITIAL		DOCU	MENT NUMBER	DATE	NAME	CL	ASS	SUB-CLASS	FILING DATE		
	AA										
	AB AC	<del> </del>									
i, 15	AD		<u> </u>								
	AE										
	AF										
	AG				<u> </u>			<u>.</u>			
	AH	<b>_</b>									
	AI	+	<u>.</u>	<b>_</b>	<del> </del>			-			
	AJ	+			<del> </del>			-			
	AK			FORE	IGN PATENT DOCUMENTS						
EXAMINER	T -						Ť				
INITIAL	-	DOCU	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION Yes		
	AL		<u>.</u>						No No		
	AM				·				Yes No		
	AN								Yes No		
	AO								Yes No		
						- **			Yes No		
	AP	1	OTHER (	Including Author	r, Title, Date, Pertiner	nt Pages, etc.	<u></u>				
QW)	AR	14 、	Roy, K. et o	al "Different	Antifolate-resistant L1 ce Synthetase Gene Expre	210 Cell Varia	nts with	either Inc mRNA Transo	creased or cription," J.		
	AS	14 *	Expression	oy, K. et al., "Posttranscriptionally Mediated Decreases in Folylpolyglutamate Synthetase Gene xpression in Some Folate Analogue-resistant Variants of the L1210 Cell," J. Biol. Chem. 72:6903-6908 (1997).							
	АТ	14	Synthetase	umberger, B.G. et al., "Differing Specificities for 4-Aminofolate Analogues of Folypolyglutamylynthetase from Tumors and Proliferative Intestinal Epiethelium of the Mouse with Significance or Selective Antitumor Action," Cancer Res. 50:4639-4643 (1990).							
EXAMINER	0	<u> </u>	, 10	1~8 ^		DATE	CONSTRE	RED (O)	<u> </u>		
EXAMINER: Ini	itial if	refere nformar	ence consider	ed, whether or r	not citation is in confo ude copy of this form w	ormance with MA	PEP 609. unication	Draw line to Applic	through ant.		
<u> </u>			<del>U</del>	<del></del>							

• •

					ATTY. DOCKET NO. APPLICATION NO. 0609.4830001 09/617,116					
			PTO-1449		APPLICANT Aghi et al.	•			M	
<u> </u>	NFORMATI	ON DIS	SCLOSURE STATI	<u>:MENI</u>	FILING DATE July 14, 2000		GROUP 1614 7 0 2 2000			
				U.S.	PATENT DOCUMENTS			E.		
EXAMINER INITIAL		DOCL	MENT NUMBER	DATE	NAME	CLA	ss	SUB-CLASS	MARY THE	
	AA									
	АВ		<u>.</u>	<u> </u>						
	AC	<b></b>								
	AD	+				-			<del>                                     </del>	
	AE					$\dashv$		-	-	
	AF AG	+				<del> </del>		-		
	AH AH	+	<del></del>							
	AI	-								
	AJ	1								
	AK							<u> </u>		
				FOREI	GN PATENT DOCUMENTS				<del></del>	
EXAMINER INITIAL		DOCL	JMENT NUMBER	DATE	COUNTRY	CLA	ss	SUB-CLASS	TRANSLATION	
	AL							·	Yes No	
	АМ								Yes No	
		$\dagger$							Yes No	
	AN		· · · · · · · · · · · · · · · · · · ·						Yes No	
	AO	+							Yes	
	AP								No	
	<u> </u>		OTHER (	Including Author	, Title, Date, Pertinent Page	es, etc.)				
QN	AR	<u>15</u>	Samuels, L. Various Fol (1985).	L. et al., "Simil ate Analogues in	lar Differential for Total Po Human and Murine Tumor Cells	lyglutamy in Vitro	vlation o," Cand	and Cytoto cer Res. 45:	xicity among 1488-1495	
	AS	<u>15</u>	Takemura, Y chemotherap	akemura, Y. and Jackman, A.L., "Folate-based thymidylate synthase inhibitors in cancer themotherapy," Anti-Cancer drugs 8:3-16 (1997).						
	AT	<u>15</u> ,	Leukaemia C	skemura, Y. $et\ al$ ., "Altered Expression of Folylpolyglutamate Synthetase (FPGS) Gene in Human eukaemia Cells with Defective Polyglutamation of Raltitrexed (ZD1694)," $Brit.\ J.\ Cancer$ of $Solution (Suppl.\ 1):31$ , Abstract No. P52 (1997).						
EXAMINER	-1	0	~ 1 n	)		DATE	CONSIDE	124/0		
EXAMINER: In	itial if	refere	ence consider	d whether or no	ot citation is in conformance ude copy of this form with ne	with MPE	P 609.	Draw line n to Applic	through	
Citation in No	7 HI COI	or mai	ice and ince c	agio raci cpi. Tricti				- PF-1-		

					ATTY. DOCKET NO. APPLICATION NO. 0609.4830001 09/617,116				010	
			PTO-1449	MENT	APPLICANT Aghi <i>et al</i> .				Tr.	
11	IFURMATI	UN DIS	SCLOSURE STATE	<u>:MENI</u>	FILING DATE July 14, 2000		GROUP 1614	SATEN	KUV 0 2 2000 G	
				U.S.	PATENT DOCUMENTS			E.		
EXAMINER INITIAL		DOCL	JMENT NUMBER	DATE	NAME	CL/	ıss	SUB-CLASS	FILING DATE	
	AA						<u> </u>			
	АВ	ļ								
	AC	<b>_</b>				-  -			-	
	AD	<del> </del>								
	AE	-		name.		-				
	AF	+	_			-		<del></del>	<del></del>	
	AG	+						<u> </u>		
	AH	+		<u></u>				<del></del>		
	AJ	+							1	
	AK									
	1 4 4 4			FOREI	GN PATENT DOCUMENTS					
EXAMINER INITIAL		DOCL	JMENT NUMBER	DATE	COUNTRY	CLA	ıss	SUB-CLASS	TRANSLATION	
	AL						-		Yes No	
			- <u>-</u>						Yes No	
	AM								Yes No	
	AN		<u>.</u>						Yes	
	AO								No Yes	
	AP								No	
CuO	AR	<u>16</u>	Taylor, S.M	et al., "Struct	, Title, Date, Pertinent Pa ural Organization of the Hu c Locus," Cancer Res. 55: 6	uman Folyl	poly-y-:	glutamate Sy	nthetase Gene:	
	AS	<u>16</u>	Terzis, A.J Antifolate (	erzis, A.J.A. $et\ al.$ , "Proliferation, Migration and Invasion of Human Glioma Cells Exposed to ntifolate Drugs," Int. J. Cancer 54:112-118 (1993).						
	AT	<u>16</u>	Kinase) but	kert, W. et al., "Double Suicide Gene (Cytosine Deaminase and Herpes Simplex Virus Thymidine nase) but Not Single Gene Transfer Allows Reliable Elimination of Tumor Cells <i>In Vivo</i> ," <i>Human ne Ther</i> . 9:855-865 (April 1998).						
EXAMINER	AL	10	~ iDon	~~~		DATE	CONSTRE	REDILES	1	
EXAMINER: Init	tient if	refere	ence consider	whether or no	ot citation is in conformand ude copy of this form with r	ce with MP	EP 609. nication	Draw line n to Applica	through	

Page 17 of 18

		FORM F	PTO-1449		ATTY. DOCKET NO. 0609.4830001  APPLICATION NO. 09/617,116					
11	NFORMATI	ON DIS	CLOSURE STATE	<u>EMENT</u>	Aghi et al.  FILING DATE July 14, 2000  GROUP 1614  GROUP 1614					
				U.S.	PATENT DOCUMENTS			Ę.	13	
EXAMINER								₹ V&	DEMARK SIE	
INITIAL	<b>_</b>	DOCU	MENT NUMBER	DATE	NAME	CLAS	S	SUB-CLASS	FILTING DATE	
	AA	╃—		ļ		+			<del></del>	
	AB	<del> </del>				+				
	AC	+				-			<del></del>	
<u> </u>	AD	-				+				
	AE	+				<del></del>	-			
	AF AG	+-								
	AH	+				1				
	AI	1								
	AJ	<u> </u>	-				-			
	AK					i				
				FORE I	GN PATENT DOCUMENTS					
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLAS	s	SUB-CLASS	TRANSLATION	
									Yes	
	AL	<del>                                     </del>				<del>                                     </del>			No Yes	
	AM	<del> </del>							No Yes	
	AN	<u> </u>	<u> </u>			+			No Yes	
	AO	-						<u>.                                    </u>	No Yes	
	AP			·					No	
			OTHER (	Including Author	, Title, Date, Pertinent Pages,	etc.)				
ON)	AR	<u>17</u>	Wei, M.X. ei Cytochrome I	t al., "Experimen 2450 2B1 Gene," h	ital Tumor Therapy in mice Using Jum. Gene Ther. 5:969-978 (1994)	the Cy	clopho	osphamide-Ad	ctivating	
	AS	<u>17</u>	Enzyme (ICE)	u, J.S. et al., "Retroviral Delivery and Tetracycline-dependent Expression of IL-1β-converting nzyme (ICE) in a Rat Glioma Model Provides Controlled Induction of Apoptotic Death in Tumor ells," Cancer Res. 56:5423-5427 (1996).						
	AT	<u>17</u> '		nang, J. and Russell, S.J., "Vectors for cancer gene therapy," Cancer & Metastasis Rev. 15:385- D1 (1996).						
EXAMINER	·	W	٩.,	~		DATE	ONS I DE	RED (	<b></b>	
EXAMINER: Initial citation if no	tial if	reiere Toman	ence considerence and not co	ed, whether or no onsidered. Inclu	ot citation is in conformance winde copy of this form with next	th MPER communi	609.	Draw line to Applica	through ant.	

Page 18 of 18

	_				ATTY. DOCKET NO. 0609.4830001 APPLICATION NO. 09/617,116					
			PTO-1449		APPLICANT Aghi et al.					
<u>IN</u>	IFORMAT I	ON DIS	CLOSURE STATE	<u>MENT</u>	FILING DATE July 14, 2000		GROUP 1614 NOV 0 2 2000			
				U.S.	PATENT DOCUMENTS		1 1014	E		
EXAMINER INITIAL		DOCII	MENT NUMBER	DATE	NAME	CL	CLASS SUB-CLASS		FILING DATE	
INTITAL	T <sub>AA</sub>	10000	MENT NOMBER	DATE	NATIO.			-	7,52.03	
	AB	1								
	AC .						_			
	AD									
	AE	<u> </u>								
	AF	<b>├</b>								
	AG	+								
· <del></del>	AH AI	<u> </u>						L		
	AJ	<del> </del>								
· <del>-</del>	AK									
	<del></del>		<del>.</del>	FOREIG	N PATENT DOCUMENTS					
EXAMINER		DOCI	MENT NUMBER	DATE	COUNTRY	CL	ASS	SUB-CLASS	TRANSLATION	
INITIAL		DOCO	MENT NOMBER	DATE	COUNTRY			000 01/100	Yes	
-	AL		· · · · ·				<u> </u>		No Yes	
, , , , , , , , , , , , , , , , , , ,	AM								No Yes	
	AN	1							No.	
	AO								Yes No	
	AP								Yes No	
	1 ***		OTHER (	Including Author	Title, Date, Pertinent P	ages, etc.	<b>)</b>			
QN	AR	<u>18</u>	Zufferey, R		ly attenuated lentiviral v			ficient gene	e delivery in	
	AS									
	AT									
EXAMINER Q	Ur.	12				DATE	CONSIDE	10 11/1	Ø)	
EXAMINER: Init	ial if	refere	nce considere	ed, whether or no onsidered. Inclu	t citation is in conforma de copy of this form with	nce with MP next commu	PEP 609. unication	Draw line	through	
2.00.,0,, 11 100	\	}	G		,,					